Alternatives to Ohtuvayre If You Can't Fill Your Prescription

Ohtuvayre (ensifentrine) is a breakthrough COPD medication, but its specialty pharmacy distribution, prior authorization requirements, and high list price mean some patients struggle to access it. If you've been prescribed Ohtuvayre and can't get it filled — or if you're waiting on insurance approval — there are other well-established COPD maintenance medications that may serve as temporary or permanent alternatives.

This guide is meant to help you have an informed conversation with your doctor about your options. Never switch COPD medications without first consulting your healthcare provider.

How Is Ohtuvayre Different From Other COPD Drugs?

Before exploring alternatives, it helps to understand what makes Ohtuvayre unique. It's a dual PDE3/PDE4 inhibitor delivered by nebulizer — the only one of its kind available for inhaled COPD maintenance. It provides both bronchodilation (relaxing airway muscles) and non-steroidal anti-inflammatory effects in a single molecule.

Other COPD maintenance drugs work through different mechanisms — primarily long-acting muscarinic antagonists (LAMAs), long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), or combinations. No other currently approved drug replicates Ohtuvayre's exact mechanism, but many options can provide meaningful COPD control.

Alternative #1: Tiotropium (Spiriva Respimat or Spiriva HandiHaler)

Tiotropium is one of the most widely used COPD maintenance medications in the world. It's a long-acting muscarinic antagonist (LAMA) that works by blocking muscarinic receptors in the airway smooth muscle, causing bronchodilation.

Brand names: Spiriva Respimat (inhaler), Spiriva HandiHaler (dry powder inhaler)

Dosing: Once daily

Key advantage: Once-daily dosing; widely covered by insurance; generics available (tiotropium bromide)

Key difference from Ohtuvayre: Bronchodilation only; no anti-inflammatory properties; uses an inhaler device, not a nebulizer

Approximate cost: $30–$80/month with insurance; generics may be lower

Alternative #2: Trelegy Ellipta (Fluticasone / Umeclidinium / Vilanterol)

Trelegy Ellipta is a once-daily triple therapy inhaler that combines an inhaled corticosteroid (ICS), a LAMA, and a LABA in one device. It's one of the most comprehensive single-inhaler COPD treatments available and is often used in patients with more severe or frequent exacerbations.

Manufacturer: GlaxoSmithKline

Dosing: Once daily via dry powder inhaler

Key advantage: Three medications in one inhaler; reduces exacerbation risk in high-risk patients; broadly covered by insurance

Key difference from Ohtuvayre: Contains a corticosteroid (Ohtuvayre is steroid-free); different device type; does not target PDE3/PDE4 pathways

Alternative #3: Breztri Aerosphere (Budesonide / Glycopyrrolate / Formoterol)

Breztri Aerosphere is another triple-combination COPD inhaler from AstraZeneca, combining an ICS (budesonide), a LAMA (glycopyrrolate), and a LABA (formoterol fumarate). It's used twice daily and is indicated for maintenance treatment in moderate-to-very severe COPD.

Dosing: Twice daily via metered-dose inhaler (MDI)

Key advantage: Well-established triple therapy; available at most retail pharmacies; broadly covered

Key difference from Ohtuvayre: Steroid-containing; inhaler device (not nebulizer); broader but different mechanism of action

Alternative #4: Roflumilast (Daliresp)

Roflumilast (brand name Daliresp) is an oral PDE4 inhibitor — the closest mechanistic relative to Ohtuvayre among approved COPD drugs. However, it only inhibits PDE4 (not PDE3), is taken as a pill once daily, and is approved for COPD patients with a chronic bronchitis phenotype and a history of frequent exacerbations.

Dosing: 500 mcg tablet, taken orally once daily

Key advantage: Oral pill (easier for patients who struggle with inhalers/nebulizers); generic available (roflumilast)

Key difference from Ohtuvayre: PDE4 only (not dual PDE3/PDE4); oral, not inhaled; common side effects include nausea, diarrhea, and weight loss; approved only for specific COPD phenotype

Comparison at a Glance

Here's a quick comparison of Ohtuvayre and its main alternatives:

Ohtuvayre (ensifentrine): Dual PDE3/PDE4 inhibitor | Nebulizer | Twice daily | Steroid-free | Specialty pharmacy | ~$2,950/month

Tiotropium (Spiriva): LAMA | Inhaler | Once daily | Steroid-free | Retail pharmacy | Lower cost

Trelegy Ellipta: ICS/LAMA/LABA | Dry powder inhaler | Once daily | Contains steroid | Retail pharmacy | Higher cost but broadly covered

Breztri Aerosphere: ICS/LAMA/LABA | MDI inhaler | Twice daily | Contains steroid | Retail pharmacy | Higher cost

Roflumilast (Daliresp): Oral PDE4 inhibitor | Pill | Once daily | Non-inhaled | Retail pharmacy | Generics available

What to Tell Your Doctor

If you're asking about alternatives to Ohtuvayre, be sure to tell your doctor:

Why you can't access Ohtuvayre (insurance denial, coverage gap, cost, etc.)

Your current COPD medications and how well they're working

Whether you prefer a nebulizer vs. inhaler vs. oral pill

Your history of COPD exacerbations in the past year

Any concerns about steroids or specific side effects

Still Trying to Get Ohtuvayre? medfinder Can Help

If you're still working on getting Ohtuvayre filled while your doctor explores alternatives, medfinder can help you identify which specialty pharmacies in your area currently have Ohtuvayre available. medfinder calls pharmacies on your behalf and texts you the results — so you spend less time on hold and more time focused on your health.

See our guide: How to Find Ohtuvayre In Stock Near You.